FDA schedules advisory committee meeting for peptides on July 23–24, 2026

• The FDA plans to convene a meeting of the Pharmacy Compounding Advisory Committee on peptides for July 23–24, 2026
• FDA scientists say the proposed plan could have no effect for the safety of peptides intended for compounding
• With regard to the proposed materials, the risks of impurities are unknown, since the FDA has not established a requirement for testing for impurities that could result from compounders’ manufacturing processes

For more on the plan, see NBC News and Ars Technica.

June 30, 2026, 3:36 PM EDT

FDA Secretary Robert F. Kennedy Jr.’s younger adviser, who is directing the agency’s efforts to loosen restrictions on peptides, says the proposed changes are not intended to harm the science behind their use.

The FDA says the proposed action would loosen restrictions on peptides intended for compounding, which are used to treat patients, but that do not have FDA approval.

Peptides are molecules made up of smaller building blocks. They may be produced in laboratories or by organisms. For example, in the body, peptides can be formed naturally and perform important functions. Some peptides are being studied for their potential medical uses, while others are marketed for other purposes.

In addition, the proposal includes a “safety” element: how the FDA would regulate peptides to ensure their safety. FDA scientists say the plan would allow peptide sellers to provide them without proper oversight.

On the other hand, the FDA plans to convene the Pharmacy Compounding Advisory Committee on July 23 and 24. Specifically, the committee will discuss whether to allow peptides BPC-157, emideltide, epitalon, KPV, MOTS-c, semax and TB-500 to be compounded. The FDA is considering whether to loosen restrictions on these peptides.

The materials include a comment letter from Aditi Gupta, who practiced in compounding in 2020–2025. In the letter, she argues that the current rules for peptides are too strict and that the FDA should allow compounding of peptides more easily. She also notes that the current rules make it difficult for researchers to access peptides.

The FDA previously published a list of new chemical terms that are used in compounds. The agency said that the proposed changes would allow compounding of peptides and other substances.

FDA scientists also say that the proposed materials could be used to support access to peptides, even though the agency does not have evidence that they are safe. They add that the FDA’s plan would not address the risks associated with impurities and contamination. They also say that the FDA’s proposed approach could allow peptide sellers to market products without proper oversight.

On the other hand, the FDA says that it is considering loosening restrictions on peptides and other substances that are used in compounding. The agency says it would require appropriate testing and quality controls.

On the other hand, the FDA plans to convene the committee to discuss whether to allow compounding of peptides and other substances. The agency says that the committee will consider risks and benefits and decide whether the proposed changes are appropriate.

Tags: Well-being/Research/USA